Rebecca A. Moss

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.7K citations · Full text

Checkmate 142, Medicine, Colorectal Cancer +8

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2K citations · Full text

Immunology, Pathology, Immunotherapeutics +18

Activation of the Receptor for Advanced Glycation End Products Triggers a p21 -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress

Harry M. Lander, James M. Tauras, Jason S. Ogiste et al. · Journal of Biological Chemistry · 1997 · 808 citations · Full text

Excess Soluble Rage, Lipid Peroxidation, Cellular Physiology +19

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

Robert L. Fine, Anthony P. Gulati, Benjamin A. Krantz et al. · Cancer Chemotherapy and Pharmacology · 2013 · 251 citations

Columbia University Experience, Pancreatic Cancer, Medicine +8

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors

Mark N. Stein, Joseph R. Bertino, Howard L. Kaufman et al. · Clinical Cancer Research · 2017 · 153 citations · Full text